NO20013701L - HER-2/neu-fusjonsproteiner - Google Patents

HER-2/neu-fusjonsproteiner

Info

Publication number
NO20013701L
NO20013701L NO20013701A NO20013701A NO20013701L NO 20013701 L NO20013701 L NO 20013701L NO 20013701 A NO20013701 A NO 20013701A NO 20013701 A NO20013701 A NO 20013701A NO 20013701 L NO20013701 L NO 20013701L
Authority
NO
Norway
Prior art keywords
fusion proteins
neu
neu fusion
nucleic acid
acid molecules
Prior art date
Application number
NO20013701A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013701D0 (no
Inventor
Martin A Cheever
Dirk Richard Gheysen
Original Assignee
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham filed Critical Smithkline Beecham
Publication of NO20013701D0 publication Critical patent/NO20013701D0/no
Publication of NO20013701L publication Critical patent/NO20013701L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20013701A 1999-01-29 2001-07-27 HER-2/neu-fusjonsproteiner NO20013701L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11797699P 1999-01-29 1999-01-29
PCT/US2000/002164 WO2000044899A1 (fr) 1999-01-29 2000-01-28 Proteines de fusion her-2/neu

Publications (2)

Publication Number Publication Date
NO20013701D0 NO20013701D0 (no) 2001-07-27
NO20013701L true NO20013701L (no) 2001-09-28

Family

ID=22375831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013701A NO20013701L (no) 1999-01-29 2001-07-27 HER-2/neu-fusjonsproteiner

Country Status (19)

Country Link
EP (1) EP1147190B1 (fr)
JP (1) JP5164300B2 (fr)
KR (1) KR100766653B1 (fr)
CN (1) CN1201004C (fr)
AT (1) ATE474048T1 (fr)
AU (1) AU780109B2 (fr)
BR (1) BR0007840A (fr)
CA (1) CA2361009C (fr)
CZ (1) CZ20012587A3 (fr)
DE (1) DE60044665D1 (fr)
ES (1) ES2348708T3 (fr)
HU (1) HUP0105303A2 (fr)
IL (1) IL144371A0 (fr)
MX (1) MXPA01007721A (fr)
NO (1) NO20013701L (fr)
NZ (1) NZ513062A (fr)
TR (1) TR200102191T2 (fr)
WO (1) WO2000044899A1 (fr)
ZA (1) ZA200106179B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (fr) 1999-09-30 2001-04-05 Corixa Corporation Compositions des proteines du stress et procedes de prevention et de traitement d'un cancer et d'une maladie infectieuse
WO2001048205A2 (fr) * 1999-12-29 2001-07-05 Corixa Corporation Sequences murines neu et procedes d"utilisation associes
WO2001074855A2 (fr) * 2000-03-30 2001-10-11 Dendreon Corporation Cellule dendritique compositions et methodes pour immunotherapie a base de cellules dendritiques
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
MXPA03001389A (es) * 2000-08-14 2004-05-04 Corixa Corp Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
PT1889630E (pt) 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d
JP2004511527A (ja) * 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP2241309A3 (fr) 2001-07-10 2012-12-26 Corixa Corporation Procédés pour encapsuler des protéines et des adjuvants dans des microsphères
CA2514058C (fr) 2003-01-24 2014-05-13 Agensys, Inc. Acides nucleiques et proteines correspondantes dites 254p1d6b utiles pour la detection et le traitement du cancer
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
NZ544017A (en) * 2003-06-25 2008-04-30 Pharmexa As A method for purification of an EGFR family derived protein recombinantly produced in an insect cell culture.
EA008827B1 (ru) 2003-06-25 2007-08-31 Фармекса А/С Очистка вариантов her-2
CA2532460C (fr) * 2003-07-21 2012-04-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Gene synthetique codant l'antigene du facteur de croissance epidermique humain 2/neu et utilisations de celui-ci
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
ITMI20041965A1 (it) 2004-10-15 2005-01-15 Augusto Amici "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici"
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2032719A2 (fr) 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Procédé pour identifier si un patient est reactif ou non a l'immunotherapie
BRPI0811228A2 (pt) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
CA2809819A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugues medicamenteux cibles a visee extracellulaire
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
EP3033111B1 (fr) 2013-08-12 2019-03-13 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
JP6425327B2 (ja) * 2013-12-12 2018-11-21 国立大学法人東京農工大学 タンパク質−磁性粒子複合体及びその製造方法
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2996902C (fr) 2015-10-02 2020-06-02 Genentech, Inc. Conjugues anticorps-medicaments de pyrrolobenzodiazepine et methodes d'utilisation
EP3362100B1 (fr) 2015-10-16 2022-06-22 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (fr) 2015-10-20 2020-07-15 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
EP3465221B1 (fr) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
MX2023000622A (es) * 2020-07-14 2023-02-22 Genentech Inc Ensayos para combinaciones de dosis fija.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4637833A2 (fr) 2022-12-23 2025-10-29 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
KR102584276B1 (ko) * 2023-03-30 2023-10-10 주식회사 애스톤사이언스 Her2 백신, 및 면역관문 억제제의 조합 요법
EP4698230A2 (fr) 2023-04-17 2026-02-25 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires
WO2026006688A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués d'anticorps de dégradation et leurs utilisations
WO2026006689A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués anticorps-dégradeur de bcl-xl et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH0914357A (ja) * 1995-06-27 1997-01-14 Honda Motor Co Ltd 伝動ベルト用ブロック

Also Published As

Publication number Publication date
JP5164300B2 (ja) 2013-03-21
DE60044665D1 (de) 2010-08-26
HK1044798A1 (en) 2002-11-01
EP1147190A1 (fr) 2001-10-24
ATE474048T1 (de) 2010-07-15
CA2361009C (fr) 2012-10-23
HUP0105303A2 (en) 2002-05-29
WO2000044899A1 (fr) 2000-08-03
KR20010101865A (ko) 2001-11-15
CA2361009A1 (fr) 2000-08-03
KR100766653B1 (ko) 2007-10-15
MXPA01007721A (es) 2003-07-14
AU780109B2 (en) 2005-03-03
NZ513062A (en) 2003-10-31
CZ20012587A3 (cs) 2002-05-15
BR0007840A (pt) 2002-01-22
NO20013701D0 (no) 2001-07-27
ZA200106179B (en) 2002-12-24
JP2002535004A (ja) 2002-10-22
IL144371A0 (en) 2002-05-23
CN1201004C (zh) 2005-05-11
AU2742600A (en) 2000-08-18
ES2348708T3 (es) 2010-12-13
CN1345374A (zh) 2002-04-17
TR200102191T2 (tr) 2001-12-21
EP1147190B1 (fr) 2010-07-14

Similar Documents

Publication Publication Date Title
NO20013701L (no) HER-2/neu-fusjonsproteiner
WO2002012341A3 (fr) Protéines de fusion her-2/neu
DK0817846T3 (da) Intracellulært domæne af HER-2/neu proteinet til forebyggelse eller behandling af maligniteter
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
MA24638A1 (fr) Vaccin
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
DK217288D0 (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
PT97103A (pt) Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
BR0207033A (pt) variantes de amina oxidase ap1
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
WO2003025002A3 (fr) Methode et compositions a base de proteines de fusion a antigene-defensine et de proteines de fusion a antigene-chimiokine utilisees comme vaccins contre les tumeurs et les infections virales
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette